Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
2009 1
2014 1
2015 2
2016 1
2017 4
2018 3
2021 1
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
New opioid receptor modulators and agonists.
Kaye AD, Cornett EM, Patil SS, Gennuso SA, Colontonio MM, Latimer DR, Kaye AJ, Urman RD, Vadivelu N. Kaye AD, et al. Best Pract Res Clin Anaesthesiol. 2018 Jun;32(2):125-136. doi: 10.1016/j.bpa.2018.06.009. Epub 2018 Jul 2. Best Pract Res Clin Anaesthesiol. 2018. PMID: 30322454 Review.
Opioids with variable properties possessing efficacy and with reduced side effects have been synthesized when compared to previously used agents. An opioid modulator is a drug that can produce both agonistic and antagonistic effects by binding to different opioid re …
Opioids with variable properties possessing efficacy and with reduced side effects have been synthesized when compared to previously used ag …
Update Psychopharmacotherapy.
Laux G. Laux G. Med Monatsschr Pharm. 2017 Jan;40(1):4-14. Med Monatsschr Pharm. 2017. PMID: 29952523 Review. English, German.
Lurasidon and the new multimodal antidepressant vortioxetine demonstrating clinical efficacy in the improvement of cognition have been withdrawn from the German market due to economic reasons based on an official committee judgement "missing additional benefit". Among new substan …
Lurasidon and the new multimodal antidepressant vortioxetine demonstrating clinical efficacy in the improvement of cognition have been withd …
Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
Müller S, Zeidler C, Ständer S. Müller S, et al. Am J Clin Dermatol. 2024 Jan;25(1):15-33. doi: 10.1007/s40257-023-00818-z. Epub 2023 Sep 17. Am J Clin Dermatol. 2024. PMID: 37717255 Free PMC article. Review.
., nemolizumab, vixarelimab/KPL-716, barzolvolimab/CDX-0159), small molecules (ruxolitinib cream, povorcitinib/INCB054707, abrocitinib) and the opioid modulator nalbuphine are highlighted. In the last past 15 years, several milestones have been reached regarding the …
., nemolizumab, vixarelimab/KPL-716, barzolvolimab/CDX-0159), small molecules (ruxolitinib cream, povorcitinib/INCB054707, abrocitinib) and …
Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity.
Ma H, Pagare PP, Li M, Neel LT, Mendez RE, Gillespie JC, Stevens DL, Dewey WL, Selley DE, Zhang Y. Ma H, et al. J Med Chem. 2023 Jan 12;66(1):577-595. doi: 10.1021/acs.jmedchem.2c01499. Epub 2022 Dec 20. J Med Chem. 2023. PMID: 36538027 Free PMC article.
The search for selective opioid ligands with desired pharmacological potency and improved safety profile has always been an area of interest. Our previous effort yielded a potent opioid modulator, NAN, a 6alpha-N-7'-indolyl-substituted naltrexamine derivative, which …
The search for selective opioid ligands with desired pharmacological potency and improved safety profile has always been an area of interest …
▼Nalmefene for alcohol dependence.
[No authors listed] [No authors listed] Drug Ther Bull. 2014 May;52(5):54-7. doi: 10.1136/dtb.2014.5.0252. Epub 2014 May 8. Drug Ther Bull. 2014. PMID: 24809337
However, until recently no drug was licensed for the management of alcohol dependence in people who are still drinking. Nalmefene (Selincro, Lundbeck), an opioid modulator licensed for the reduction of alcohol consumption, was launched in the UK in May 2013.6,7 Here …
However, until recently no drug was licensed for the management of alcohol dependence in people who are still drinking. Nalmefene (Selincro, …
Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.
Callaghan CK, Rouine J, Dean RL, Knapp BI, Bidlack JM, Deaver DR, O'Mara SM. Callaghan CK, et al. Brain Behav Immun. 2018 Jan;67:152-162. doi: 10.1016/j.bbi.2017.08.016. Epub 2017 Aug 24. Brain Behav Immun. 2018. PMID: 28844812
We also investigate the potential of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid modulator (antagonist at mu and partial agonist at kappa and delta opioid receptors in vitro), to reverse IFN-alpha induced changes. ...
We also investigate the potential of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid modulator (antagonist at mu …
Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist.
Shram MJ, Silverman B, Ehrich E, Sellers EM, Turncliff R. Shram MJ, et al. J Clin Psychopharmacol. 2015 Jun;35(3):242-9. doi: 10.1097/JCP.0000000000000320. J Clin Psychopharmacol. 2015. PMID: 25928699 Free PMC article. Clinical Trial.
A novel clinical study design was used to evaluate the blockade of a selective short-acting mu-opioid agonist (remifentanil) in 24 opioid-experienced subjects. Samidorphan (3-carboxamido-4-hydroxynaltrexone) is a novel opioid modulator with mu-antagonist properties. …
A novel clinical study design was used to evaluate the blockade of a selective short-acting mu-opioid agonist (remifentanil) in 24 opioid-ex …
Effects of Nalbuphine on Gastrointestinal Function in Post-Operative Critical Ill Patients Admitted to the ICU: A Multicenter Randomized Controlled Trial.
Yan Y, Lei C, Su B, Dong E, Wang G, Li B, Li X, Li A, Gan G, Chen Y, Zhang X. Yan Y, et al. Front Med (Lausanne). 2022 Feb 16;9:836872. doi: 10.3389/fmed.2022.836872. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35252270 Free PMC article.
The administration of opioids for pain reduction is thought to contribute to GI dysfunction. We tested whether nalbuphine, a mixed agonist/antagonist opioid modulator, can promote GI recovery in postoperative critical patients admitted to the intensive care unit (IC …
The administration of opioids for pain reduction is thought to contribute to GI dysfunction. We tested whether nalbuphine, a mixed agonist/a …
15 results